DUBLIN–(BUSINESS WIRE)–The “Global
Type 1 Diabetes Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.
Type 1 Diabetes Pipeline Highlights – 2019, provides most the
up-to-date information on key pipeline products in the global Type 1
Diabetes market. It covers emerging therapies for Type 1 Diabetes in
active clinical development stages including early and late stage
clinical trials. The pipeline data presented in this report helps
executives in tracking competition, identifying partners, evaluating
opportunities, formulating business development strategies, and
executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Type 1 Diabetes pipeline products by clinical trial
stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Type 1 Diabetes pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.
Company:
The report provides Type 1 Diabetes pipeline products by the company.
Short-term Launch Highlights:
Find out which Type 1 Diabetes pipeline products will be launched in the
US and Ex-US to 2024.
Summary:
- Type 1 Diabetes phase 3 clinical trial pipeline products
- Type 1 Diabetes phase 2 clinical trial pipeline products
- Type 1 Diabetes phase 1 clinical trial pipeline products
- Type 1 Diabetes preclinical research pipeline products
- Type 1 Diabetes discovery stage pipeline products
- Type 1 Diabetes pipeline products short-term launch highlights
Key Topics Covered:
1. Type 1 Diabetes Pipeline by Stages
2. Type 1 Diabetes Phase 3 Clinical Trial Insights
3. Type 1 Diabetes Phase 2 Clinical Trial Insights
4. Type 1 Diabetes Phase 1 Clinical Trial Insights
5. Type 1 Diabetes Preclinical Research Insights
6. Type 1 Diabetes Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/goltbz
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Endocrine
and Metabolic Disorders Drugs, Diabetes
Drugs